Creon® can optimise nutritional status & normalise digestion, pain & bowel movements in patients with pancreatic exocrine insufficiency (PEI).1,2
Since PEI is caused by a lack of pancreatic enzymes, treatments such as Creon (pancreatic extract) contain the extra enzymes the body needs. These treatments are called PERT - Pancreatic Enzyme Replacement Therapy.
Pancreatic Exocrine Insufficiency (PEI)
When the pancreas produces less than 10% of the normal amount of lipase units, the body cannot break down enough fat to maintain normal digestion. When this happens, important fats and nutrients cannot be extracted and absorbed from the food that we eat, and are instead passed through the body as waste, resulting in fatty, smelly and unpleasant diarrhoea. This condition is referred to as Pancreatic Exocrine Insufficiency.
PEI IS A MAJOR CONSEQUENCE OF A WIDE RANGE OF PANCREATIC CONDITIONS/DISEASES3-11. PERT IS THE GOLD STANDARD THERAPY FOR PEI1,3For patients with PEI:
- Creon® reduces PEI symptoms and improves nutritional status2,12-14
- Creon® improves quality of life12,13
- Creon® has a well-established safety profile1,8,15,16
- An optimal dose* to reduce daily pill burden
- May assist with adherence to PERT
*Compared with Creon® 25000
PERT: pancreatic enzyme replacement therapy
- Creon® Approved Product Information. 24 January 2022.
- Ramesh H, et al. Pancreatology. 2013; 13:133-9.
- Smith RC, et al.Australasian guidelines for the management of pancreatic exocrine insufficiency. Australasian Pancreatic Club, October 2015. Available at: https://www.pan-creas.org. au/resources (accessed November 2021).
- Löhr JM, et al. United European Gastroenterol J 2017; 5 (2):153–99.
- Keller J et al., Gut 2005; 54(Suppl VI):vi1–vi28.
- Nakajima K, et al. Core evidence 2012;7:77-91.
- Conwell D, et al. Pancreas 2014;43;1143-62.
- Cystic Fibrosis Nutrition Guideline Authorship Group (2017). Nutrition Guidelines for Cystic Fibrosis in Australia and New Zealand, ed. Scott C. Bell, Thoracic Society of Australia and New Zealand, Sydney. Available at: https://www.thoracic.org.au/documents/item/1045 (accessed November 2021).
- Dominguez-Munoz JE. HPB. 2009;11 Suppl 3:3-6.
- Mohaprata S. et al. Pancreas 2016;45;8:1104-10.
- Evans K, et al. Dig Dis Sci. 2010;55:299-3004.
- D’Haese JG, et al. Pancreas. 2014;43(6):834-41.
- Safdi M, et al. Pacreas. 2006;33(2):156-62.
- Seller CM et al. Aliment Pharmacol Ther. 2013;37(7):691-702.
- Dominguez-Munoz JE, et al. Clin Gastro & Hep. 2007; 5:484-88.
- Kuhn RJ, et al. Adv Ther. 2010;27(12):895-916.
- Stern RC, et al. Am J Gastroenterol. 2000; 95(8):1932-8.
- Pharmaceutical Benefits Scheme. 1 July 2021.
PI & PBS Information
PBS Information: Creon is listed on the PBS as a Digestive enzyme preparation (10 repeats).
Restricted benefit: for cystic fibrosis patients under a GP Management Plan or Team Care Arrangement (21 repeats).
Before prescribing, please review the full Product Information available here.
Signs & Symptoms
The pancreas is an organ in the digestive system which produces several important hormones as well as pancreatic juice. Pancreatic juice contains digestive enzymes (including lipases) which help the body to absorb nutrients and break down the proteins, fats and carbohydrates found in food. During a meal a healthy pancreas will release thousands of lipase units (a type of digestive enzyme).
Possible Symptoms of PEI
Short-term – abdominal (tummy) pain, fatty stools, diarrhoea, increased wind and weight loss.
Long-term – more serious conditions like malnutrition, which may lead to further complications.
Dosing & Administration
The Creon® Dosing Range
- Increase Creon® dose if required to control gastrointestinal symptoms and maintain good nutritional status1,2,3
- Maximum DAILY dose 10,000 units lipase/kg bodyweight1
- Maximum MEAL dose 80,000 units1
- Low fat diet is not required or recommended when on Creon® therapy1,2
- Creon® Approved Product Information
- Smith RC, et al.Australasian guidelines for the management of pancreatic exocrine insufficiency. Australasian Pancreatic Club, October 2015. Available at: https://www.pancreas.org. au/resources (accessed November 2021).
- Löhr JM, et al. United European Gastroenterol J 2017;
Transient and Persistent Pancreatic Enzyme Insufficiency
Dr Stephen Philcox, Gastroenterologist, John Hunter Hospital New South Wales
Dr Philcox shares a case study that concentrated on persistent PEI, and its management, in a previously well 61-year-old man who presented to the emergency department with abdominal pain and nausea. The patients’ medical history was unremarkable with no significant family history, no regular medications and reported low intake of alcohol; however, his lipase was extremely high at 27,483 U/L.
In this video you’ll see Dr Philcox open the discussion to the multidisciplinary panel for their input on how best to manage the case going forward, including the use of pancreatic enzyme replacement therapy (PERT) and present the evidence that supports it.
Video Creon Case Study 1 - Presented by Prof Benedict Devereaux
Prof Benedict Devereaux, Senior Consultant Gastroenterologist, Royal Brisbane and Women’s Hospital.
Professor Devereaux shares the history of a 45-year old man who was admitted to the emergency department with severe abdominal pain. The patient reported repeated episodes of abdominal pain prior to this presentation, a history of recurrent acute pancreatitis, nicotine dependence (20-25 cigarettes per day), and although he only drank “the occasional beer” currently, he did have a history of heavy alcohol consumption.
In this video, you’ll see a panel of experts discuss interpreting the CT findings, the impact of smoking, endoscopic retrograde cholangiopancreatography findings and their consensus on different management strategies.
Creon Patient Booklet
Your guide to pancreatic exocrine insufficiency and Creon
This booklet is an educational resource for people taking Creon. It is not designed to replace the advice of your healthcare professional. Please also refer to the Creon Consumer Medicine Information which is available from your doctor or pharmacist. Please consult your doctor if you have any further questions about your condition or the benefits and risks of Creon. References to any services, websites or other information by trademark or otherwise is not intended to imply the endorsement, sponsorship or recommendation by Viatris Inc.
Creon Patient Diary
Who is this patient booklet for?
Living with the symptoms of pancreatic exocrine insufficiency (PEI) can be unpleasant for your patients and may lead them to live a less enjoyable life than they are used to.
Creon is indicated as a pancreatic enzyme replacement therapy (PERT) in paediatic and adult patients with PEI. This booklet is designed to help patients understand a little more about PEI and how to achieve (and maintain) the best results from their Creon medication.
This patient booklet covers:
- What PEI is
- Symptoms of PEI
- What Creon is
- How to take Creon
- Side effects
- What experts are saying
- Diet and Exercise
- Support for PEI patients
We have created a comprehensive patient booklet for your Pancreatic Exocrine Insufficiency patients.